CRSP:NSD-CRISPR Therapeutics AG (USD)

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing

USD 36.86

Change

0.00 (0.00)%

Market Cap

USD 0.79B

Volume

1.26M

Analyst Target

USD 95.21
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

CRISPR Therapeutics AG is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+10.00 (+2.29%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

+14.92 (+2.54%)

USD 65.38B
ARGX argenx NV ADR

-7.84 (-1.33%)

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

+0.14 (+0.05%)

USD 32.75B
ONC BeiGene, Ltd.

-3.12 (-1.29%)

USD 27.70B
SMMT Summit Therapeutics PLC

-0.21 (-0.81%)

USD 27.07B
RPRX Royalty Pharma Plc

+0.24 (+0.74%)

USD 18.40B
INSM Insmed Inc

+0.49 (+0.73%)

USD 11.84B
INCY Incyte Corporation

+1.11 (+1.72%)

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

+0.56 (+0.97%)

USD 11.29B

ETFs Containing CRSP

XDNA 15.28 % 0.00 %

N/A

N/A
ARCG:LSE ARK Genomic Revolution UC.. 8.40 % 0.00 %

+10.43 (+3.67%)

USD 8.76M
ARKG:LSE ARK Genomic Revolution UC.. 8.40 % 0.00 %

+0.15 (+3.67%)

USD 8.76M
ARKG ARK Genomic Revolution ET.. 8.37 % 0.75 %

+0.61 (+3.67%)

USD 0.89B
ARCK:LSE ARK Innovation UCITS ETF .. 4.47 % 0.00 %

+15.03 (+3.67%)

USD 0.04B
ARKK:LSE ARK Innovation UCITS ETF .. 4.47 % 0.00 %

+0.21 (+3.67%)

USD 0.04B
ARKK ARK Innovation ETF 4.46 % 0.75 %

+1.98 (+3.67%)

USD 5.62B
GN0M:XETRA Global X Genomics & Biote.. 4.46 % 0.00 %

-0.01 (3.67%)

USD 7.05M
GNOG:LSE Global X Genomics & Biote.. 4.42 % 0.00 %

+0.05 (+3.67%)

USD 8.06M
GNOM:SW 4.42 % 0.00 %

N/A

N/A
GNOM Global X Genomics & Biote.. 4.11 % 0.00 %

+0.06 (+3.67%)

USD 0.04B
NXTE Investment Managers Serie.. 4.01 % 0.00 %

+0.46 (+3.67%)

N/A
LS:CA 3.11 % 2.21 %

N/A

N/A
CDNA:CA 2.65 % 0.00 %

N/A

N/A
WRNA:XETRA WisdomTree BioRevolution .. 2.09 % 0.00 %

N/A

USD 2.77M
WBIO:LSE WisdomTree BioRevolution .. 2.07 % 0.00 %

+13.25 (+3.67%)

USD 3.68M
WDNA WisdomTree BioRevolution .. 2.05 % 0.00 %

-0.04 (3.67%)

USD 1.98M
AIIQ 0.00 % 0.79 %

N/A

N/A
ERSX 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.35% 69% C- 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.35% 69% C- 48% F
Trailing 12 Months  
Capital Gain -33.27% 56% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.27% 56% F 29% F
Trailing 5 Years  
Capital Gain -42.34% 68% D+ 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.34% 67% D+ 28% F
Average Annual (5 Year Horizon)  
Capital Gain -12.45% 37% F 22% F
Dividend Return -12.45% 37% F 21% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 37.06% 76% C+ 48% F
Risk Adjusted Return -33.61% 32% F 22% F
Market Capitalization 0.79B 93% A 85% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.53 36% 60%
Price/Book Ratio 1.71 55% 51%
Price / Cash Flow Ratio -23.66 94% 91%
Price/Free Cash Flow Ratio 14.16 6% 27%
Management Effectiveness  
Return on Equity -19.20% 88% 43%
Return on Invested Capital -24.65% 70% 30%
Return on Assets -13.04% 84% 31%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector